Immunic Inc. Stock
Price
Target price
€0.75
€0.75
-3.570%
-0.028
-3.570%
€6.89
24.04.26 / Tradegate
WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Immunic
sharewise wants to provide you with the best news and tools for Immunic, so we directly link to the best financial data sources.
Financials
News
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
EQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
EQS-News: Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
EQS-News: Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
EQS-News: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
EQS-News: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
EQS-News: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
EQS-News: Immunic to Participate in Investor and Medical Conferences in May
EQS-News: Immunic to Participate in Investor and Medical Conferences in May
EQS-News: Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
EQS-News: Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
EQS-News: Immunic, Inc. Announces 1-for-10 Reverse Stock Split
EQS-News: Immunic, Inc. Announces 1-for-10 Reverse Stock Split
EQS-News: Immunic to Participate in Scientific and Medical Conferences in April
EQS-News: Immunic to Participate in Scientific and Medical Conferences in April
EQS-News: Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
EQS-News: Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
EQS-News: Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
EQS-News: Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
EQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones